|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Cardiovascular Research Institute, Comprehensive Cancer Center, and Department of Anatomy, University of California, San Francisco, San Francisco, California, USA
2 Hematology Division, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
3 Regeneron Pharmaceuticals, Tarrytown, New York, USA
4 Cardiology Division, Department of Medicine, University of California, San Francisco, San Francisco, California, USA
* To whom correspondence should be addressed. E-mail: dmcd{at}itsa.ucsf.edu.
Blood vessels in the adult, unlike during development, are generally thought not to require VEGF for normal function. However, VEGF is a survival factor for many tumor vessels, and there are clues that some normal blood vessels may also depend on VEGF. In this study, we sought to identify which, if any, vascular beds in adult mice depend on VEGF for survival. Mice were treated with a small molecule VEGF receptor (VEGFR) tyrosine kinase inhibitor or soluble VEGFRs for 1 to 3 weeks. Blood vessels were assessed by immunohistochemistry or scanning or transmission electron microscopy. In a study of 17 normal organs after VEGF inhibition, we found significant capillary regression in pancreatic islets, thyroid, adrenal cortex, pituitary, choroid plexus, small intestinal villi, and epididymal adipose tissue. The amount of regression was dose-dependent and varied from organ to organ, with a maximum of 68% in thyroid, but was less in normal organs than in tumors in RIP-Tag2 transgenic mice or in Lewis lung carcinoma. VEGF-dependent capillaries were fenestrated, expressed high levels of both VEGFR-2 and VEGFR-3, and had normal pericyte coverage. Surviving capillaries in affected organs had fewer fenestrations and less VEGFR expression. All mice appeared healthy, but distinct physiological changes, including more efficient blood glucose handling, accompanied some regimens of VEGF inhibition. Strikingly, most capillaries in the thyroid grew back within 2 weeks after cessation of treatment for one week. Our findings of VEGF-dependency of normal fenestrated capillaries and rapid regrowth after regression illustrate the plasticity of the adult microvasculature.
This article has been cited by other articles:
![]() |
M. Saint-Geniez, T. Kurihara, E. Sekiyama, A. E. Maldonado, and P. A. D'Amore An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris PNAS, November 3, 2009; 106(44): 18751 - 18756. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Whee Park, H. Wook Kim, J. Hee Lim, K. Dong Yoo, S. Chung, S. Joon Shin, H. Wha Chung, S. Ju Lee, C.-B. Chae, Y.-S. Kim, et al. Vascular Endothelial Growth Factor Inhibition by dRK6 Causes Endothelial Apoptosis, Fibrosis, and Inflammation in the Heart via the Akt/eNOS Axis in db/db Mice Diabetes, November 1, 2009; 58(11): 2666 - 2676. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Suzuki, A. Ohkuchi, S. Matsubara, Y. Takei, M. Murakami, M. Shibuya, M. Suzuki, and Y. Sato Effect of Recombinant Placental Growth Factor 2 on Hypertension Induced by Full-Length Mouse Soluble fms-Like Tyrosine Kinase 1 Adenoviral Vector in Pregnant Mice Hypertension, November 1, 2009; 54(5): 1129 - 1135. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Steeghs, T. J. Rabelink, J. op 't Roodt, E. Batman, F. H. M. Cluitmans, N. I. Weijl, E. de Koning, and H. Gelderblom Reversibility of capillary density after discontinuation of bevacizumab treatment Ann. Onc., October 23, 2009; (2009) mdp417v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Zangari, L. M. Fink, F. Elice, F. Zhan, D. M. Adcock, and G. J. Tricot Thrombotic Events in Patients With Cancer Receiving Antiangiogenesis Agents J. Clin. Oncol., October 10, 2009; 27(29): 4865 - 4873. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. S. Facemire, A. B. Nixon, R. Griffiths, H. Hurwitz, and T. M. Coffman Vascular Endothelial Growth Factor Receptor 2 Controls Blood Pressure by Regulating Nitric Oxide Synthase Expression Hypertension, September 1, 2009; 54(3): 652 - 658. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. E. Walshe, V. S. Dole, A. S.R. Maharaj, I. S. Patten, D. D. Wagner, and P. A. D'Amore Inhibition of VEGF or TGF-{beta} Signaling Activates Endothelium and Increases Leukocyte Rolling Arterioscler Thromb Vasc Biol, August 1, 2009; 29(8): 1185 - 1192. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Nakagawa, T. Kosugi, M. Haneda, C. J. Rivard, and D. A. Long Abnormal Angiogenesis in Diabetic Nephropathy Diabetes, July 1, 2009; 58(7): 1471 - 1478. [Full Text] [PDF] |
||||
![]() |
T. Okazaki, A. Ni, O. A. Ayeni, P. Baluk, L.-C. Yao, D. Vossmeyer, G. Zischinsky, G. Zahn, J. Knolle, C. Christner, et al. {alpha}5{beta}1 Integrin Blockade Inhibits Lymphangiogenesis in Airway Inflammation Am. J. Pathol., June 1, 2009; 174(6): 2378 - 2387. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. Satchell and F. Braet Glomerular endothelial cell fenestrations: an integral component of the glomerular filtration barrier Am J Physiol Renal Physiol, May 1, 2009; 296(5): F947 - F956. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. M. Olfert, R. A. Howlett, K. Tang, N. D. Dalton, Y. Gu, K. L. Peterson, P. D. Wagner, and E. C. Breen Muscle-specific VEGF deficiency greatly reduces exercise endurance in mice J. Physiol., April 15, 2009; 587(8): 1755 - 1767. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. R. Cuddihy, S. Ge, J. Zhu, J. Jang, A. Chidgey, G. Thurston, R. Boyd, and G. M. Crooks VEGF-mediated cross-talk within the neonatal murine thymus Blood, March 19, 2009; 113(12): 2723 - 2731. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. S. Funa, V. Kriz, G. Zang, G. Calounova, B. Akerblom, J. Mares, E. Larsson, Y. Sun, C. Betsholtz, and M. Welsh Dysfunctional Microvasculature as a Consequence of Shb Gene Inactivation Causes Impaired Tumor Growth Cancer Res., March 1, 2009; 69(5): 2141 - 2148. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Ma and D. J. Waxman Dominant Effect of Antiangiogenesis in Combination Therapy Involving Cyclophosphamide and Axitinib Clin. Cancer Res., January 15, 2009; 15(2): 578 - 588. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Saint-Geniez, T. Kurihara, and P. A. D'Amore Role of Cell and Matrix-Bound VEGF Isoforms in Lens Development Invest. Ophthalmol. Vis. Sci., January 1, 2009; 50(1): 311 - 321. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Mu, D. A. Long, X. Ouyang, A. Agarwal, P. E. Cruz, C. A. Roncal, T. Nakagawa, X. Yu, W. W. Hauswirth, and R. J. Johnson Angiostatin overexpression is associated with an improvement in chronic kidney injury by an anti-inflammatory mechanism Am J Physiol Renal Physiol, January 1, 2009; 296(1): F145 - F152. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Patyna, C. Arrigoni, A. Terron, T.-W. Kim, J. K. Heward, S. L. Vonderfecht, R. Denlinger, S. E. Turnquist, and W. Evering Nonclinical Safety Evaluation of Sunitinib: A Potent Inhibitor of VEGF, PDGF, KIT, FLT3, and RET Receptors Toxicol Pathol, December 1, 2008; 36(7): 905 - 916. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Ma and D. J. Waxman Combination of antiangiogenesis with chemotherapy for more effective cancer treatment Mol. Cancer Ther., December 1, 2008; 7(12): 3670 - 3684. [Abstract] [Full Text] [PDF] |
||||
![]() |
L J Singerman, H Masonson, M Patel, A P Adamis, R Buggage, E Cunningham, M Goldbaum, B Katz, and D Guyer Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial Br J Ophthalmol, December 1, 2008; 92(12): 1606 - 1611. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. E.W. Cohen, L. S. Rosen, E. E. Vokes, M. S. Kies, A. A. Forastiere, F. P. Worden, M. A. Kane, E. Sherman, S. Kim, P. Bycott, et al. Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study J. Clin. Oncol., October 10, 2008; 26(29): 4708 - 4713. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Olerud, M. Johansson, J. Lawler, N. Welsh, and P.-O. Carlsson Improved Vascular Engraftment and Graft Function After Inhibition of the Angiostatic Factor Thrombospondin-1 in Mouse Pancreatic Islets Diabetes, July 1, 2008; 57(7): 1870 - 1877. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Heckman, T. Holopainen, M. Wirzenius, S. Keskitalo, M. Jeltsch, S. Yla-Herttuala, S. R. Wedge, J. M. Jurgensmeier, and K. Alitalo The Tyrosine Kinase Inhibitor Cediranib Blocks Ligand-Induced Vascular Endothelial Growth Factor Receptor-3 Activity and Lymphangiogenesis Cancer Res., June 15, 2008; 68(12): 4754 - 4762. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. N. Gavrilovskaya, E. E. Gorbunova, N. A. Mackow, and E. R. Mackow Hantaviruses Direct Endothelial Cell Permeability by Sensitizing Cells to the Vascular Permeability Factor VEGF, while Angiopoietin 1 and Sphingosine 1-Phosphate Inhibit Hantavirus-Directed Permeability J. Virol., June 15, 2008; 82(12): 5797 - 5806. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Tatar, E. Yoeruek, P. Szurman, K. U. Bartz-Schmidt, A. Adam, K. Shinoda, C. Eckardt, V. Boeyden, C. Claes, G. Pertile, et al. Effect of Bevacizumab on Inflammation and Proliferation in Human Choroidal Neovascularization Arch Ophthalmol, June 1, 2008; 126(6): 782 - 790. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. A. Bryan, T. E. Walshe, D. C. Mitchell, J. S. Havumaki, M. Saint-Geniez, A. S. Maharaj, A. E. Maldonado, and P. A. D'Amore Coordinated Vascular Endothelial Growth Factor Expression and Signaling During Skeletal Myogenic Differentiation Mol. Biol. Cell, March 1, 2008; 19(3): 994 - 1006. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S.R. Maharaj, T. E. Walshe, M. Saint-Geniez, S. Venkatesha, A. E. Maldonado, N. C. Himes, K. S. Matharu, S. A. Karumanchi, and P. A. D'Amore VEGF and TGF-{beta} are required for the maintenance of the choroid plexus and ependyma J. Exp. Med., February 18, 2008; 205(2): 491 - 501. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Heiss, R. E. Sievers, N. Amabile, T. Y. Momma, Q. Chen, S. Natarajan, Y. Yeghiazarians, and M. L. Springer In vivo measurement of flow-mediated vasodilation in living rats using high-resolution ultrasound Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H1086 - H1093. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Ma and D. J. Waxman Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib Mol. Cancer Ther., January 1, 2008; 7(1): 79 - 89. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Rudge, J. Holash, D. Hylton, M. Russell, S. Jiang, R. Leidich, N. Papadopoulos, E. A. Pyles, A. Torri, S. J. Wiegand, et al. Inaugural Article: VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade PNAS, November 20, 2007; 104(47): 18363 - 18370. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Grothey Biological Therapy and Other Novel Therapies in Early-Stage Disease: Are They Appropriate? Clin. Cancer Res., November 15, 2007; 13(22): 6909s - 6912s. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Vartanian and R. Sarkar Therapeutic Angiogenesis Vascular and Endovascular Surgery, July 1, 2007; 41(3): 173 - 185. [Abstract] [PDF] |
||||
![]() |
N. L. Ward, E. Moore, K. Noon, N. Spassil, E. Keenan, T. L. Ivanco, and J. C. LaManna Cerebral angiogenic factors, angiogenesis, and physiological response to chronic hypoxia differ among four commonly used mouse strains J Appl Physiol, May 1, 2007; 102(5): 1927 - 1935. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Maitland and M. J. Ratain Terminal ballistics of kinase inhibitors: there are no magic bullets. Ann Intern Med, November 7, 2006; 145(9): 702 - 703. [Full Text] [PDF] |
||||
![]() |
D. G. Duda Antiangiogenesis and drug delivery to tumors: bench to bedside and back. Cancer Res., April 15, 2006; 66(8): 3967 - 3970. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Betsholtz and A. Armulik Homeostatic functions of vascular endothelial growth factor in adult microvasculature Am J Physiol Heart Circ Physiol, February 1, 2006; 290(2): H509 - H511. [Full Text] [PDF] |
||||
![]() |
F. Baffert, T. Le, B. Sennino, G. Thurston, C. J. Kuo, D. Hu-Lowe, and D. M. McDonald Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling Am J Physiol Heart Circ Physiol, February 1, 2006; 290(2): H547 - H559. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |